Open AccessSafety of pathogenetic therapy for multiple sclerosis during the COVID-19 pandemic
Author(s) -
А. М. Петров,
М. В. Вотинцева,
I. D. Stolyarov
Publication year - 2022
Publication title -
annals of clinical and experimental neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.118
H-Index - 2
eISSN - 2409-2533
pISSN - 2075-5473
DOI - 10.54101/acen.2022.2.8
Subject(s) - natalizumab , medicine , fingolimod , ocrelizumab , multiple sclerosis , teriflunomide , glatiramer acetate , alemtuzumab , adverse effect , pandemic , progressive multifocal leukoencephalopathy , intensive care medicine , immunology , covid-19 , pharmacology , disease , rituximab , lymphoma , infectious disease (medical specialty) , antibody
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom